Get the Stockscreener App
7.94
2.82%
-0.23
After Hours:
8.01
0.07
+0.88%
Evolent Health Inc stock is traded at $7.94, with a volume of 2.90M.
It is down -2.82% in the last 24 hours and down -13.60% over the past month.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
See More
Previous Close:
$8.17
Open:
$8.22
24h Volume:
2.90M
Relative Volume:
0.99
Market Cap:
$933.02M
Revenue:
$2.35B
Net Income/Loss:
$-74.42M
P/E Ratio:
-8.4468
EPS:
-0.94
Net Cash Flow:
$150.93M
1W Performance:
-3.52%
1M Performance:
-13.60%
6M Performance:
-19.72%
1Y Performance:
-70.37%
1-Day Range:
$7.905
$8.33
1-Week Range:
$7.87
$8.4599
52-Week Range:
$7.06
$27.42
Evolent Health Inc Stock (EVH) Company Profile
Name
Evolent Health Inc
Sector
Industry
Phone
571-389-6000
Address
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Compare EVH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
7.94 | 947.48M | 2.35B | -74.42M | 150.93M | -0.94 |
|
VEEV
Veeva Systems Inc
|
286.59 | 48.92B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
96.39 | 17.25B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
65.61 | 13.59B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
90.52 | 7.99B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.70 | 7.14B | 906.14M | -52.62M | 89.62M | -0.3621 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Needham | Buy |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Nov-08-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-09-24 | Upgrade | Truist | Hold → Buy |
| Apr-22-24 | Initiated | Citigroup | Buy |
| Mar-01-24 | Initiated | Oppenheimer | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-23 | Initiated | UBS | Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Nov-01-22 | Initiated | Truist | Hold |
| Jul-29-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Nov-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-29-21 | Resumed | JP Morgan | Neutral |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Jul-06-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-05-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-05-18 | Resumed | Leerink Partners | Outperform |
| Jun-04-18 | Initiated | Piper Jaffray | Overweight |
| Apr-24-18 | Resumed | JP Morgan | Neutral |
| Sep-20-17 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-02-17 | Initiated | Robert W. Baird | Outperform |
| Mar-14-17 | Initiated | Oppenheimer | Outperform |
| Jan-13-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Oct-28-16 | Resumed | JP Morgan | Overweight |
| Aug-05-16 | Reiterated | FBR Capital | Outperform |
| Jul-26-16 | Initiated | Jefferies | Buy |
| Jul-13-16 | Reiterated | FBR Capital | Outperform |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Jan-06-16 | Initiated | Canaccord Genuity | Buy |
| Jun-30-15 | Initiated | Goldman | Buy |
| Jun-30-15 | Initiated | JP Morgan | Overweight |
| Jun-30-15 | Initiated | Leerink Partners | Outperform |
| Jun-30-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Evolent Health Inc Stock (EVH) Latest News
What moving averages say about Evolent Health Inc.July 2025 Recap & AI Based Trade Execution Alerts - newser.com
Will Evolent Health Inc. stock go up soonWeekly Volume Report & Target Return Focused Picks - newser.com
Will Evolent Health Inc Class stock top growth indexesJuly 2025 Opening Moves & Expert Verified Stock Movement Alerts - newser.com
Will Evolent Health Inc. (9EH) stock sustain uptrend momentumTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Is Evolent Health Inc. still worth holding after the dipEarnings Performance Report & Risk Managed Trade Strategies - newser.com
How Evolent Health Inc. stock reacts to global recession fearsWeekly Investment Summary & High Accuracy Swing Trade Signals - newser.com
Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Citizen Tribune
Q3 2025 Results Nov. 6 — Evolent to Report Q3 financials, host 5 p.m. ET call and webcast of investor conferences - Stock Titan
Does Evolent Health Inc. qualify in momentum factor screeningMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Advanced analytics toolkit walkthrough for Evolent Health Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
Momentum divergence signals in Evolent Health Inc. chartJuly 2025 Institutional & Risk Controlled Daily Plans - newser.com
Volume spikes in Evolent Health Inc. stock – what they mean2025 Geopolitical Influence & Accurate Buy Signal Alerts - newser.com
Will Evolent Health Inc Class stock extend growth storyJuly 2025 Setups & Fast Entry Momentum Trade Alerts - newser.com
Is Evolent Health Inc a good long term investmentLong-Term Investment Plans & Amplify Gains With Picks - earlytimes.in
Real time scanner hits for Evolent Health Inc. explainedInsider Selling & Free Daily Entry Point Trade Alerts - newser.com
Using RSI to spot recovery in Evolent Health Inc.Weekly Gains Summary & Breakout Confirmation Trade Signals - newser.com
Is Evolent Health Inc. meeting your algorithmic filter criteriaJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Evolent Health Inc. stock outperform growth indexes2025 Earnings Impact & Momentum Based Trading Ideas - newser.com
Can Addictive Learning Technology Limited (LAWSIKHO) Maintain Its ValuationSwing Trading Watchlist & Identify Winning Stocks - earlytimes.in
Evaluating Evolent Health (EVH): Is the Recent Decline a Sign of Undervaluation? - Yahoo Finance
Will Evolent Health Inc. (9EH) stock extend growth storyMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
Why Evolent Health Inc. (9EH) stock is a must watch tickerJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Assessing Evolent Health (EVH) Valuation Following a Sharp 18% Share Price Decline - Sahm
Candlestick signals on Evolent Health Inc. stock todayTrade Performance Summary & Free Real-Time Market Sentiment Alerts - newser.com
Will Evolent Health Inc. (9EH) stock gain from green policiesMarket Volume Summary & Safe Capital Growth Tips - newser.com
Can you recover from losses in Evolent Health Inc.Market Activity Summary & Accurate Entry/Exit Alerts - newser.com
Evolent Health Inc Class A (EVH) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
BTIG Reiterates "Buy" Rating for Evolent Health (EVH) with Price Target of $20 | EVH Stock News - GuruFocus
Forecasting The Future: 6 Analyst Projections For Evolent Health - Benzinga
Evolent Health Inc Stock (EVH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evolent Health Inc Stock (EVH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCarthy Daniel Joseph | PRESIDENT |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
389,004 |
| Jelinek Richard M | Director |
Mar 07 '25 |
Buy |
9.12 |
30,000 |
273,750 |
15,000 |
| GRUA PETER J | Director |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
18,749 |
| Blackley Seth | Chief Executive Officer |
Mar 06 '25 |
Buy |
9.01 |
55,225 |
497,577 |
762,217 |
| Springstubb Brendan B | Director |
Mar 07 '25 |
Buy |
9.27 |
15,000 |
139,050 |
26,842 |
| Glass Russell Monroe | Director |
Mar 06 '25 |
Buy |
9.27 |
5,400 |
50,058 |
14,272 |
| KECK KIM | Director |
Mar 07 '25 |
Buy |
9.44 |
10,540 |
99,498 |
39,522 |
| Barbarosh Craig A. | Director |
Mar 06 '25 |
Buy |
8.81 |
2,000 |
17,620 |
31,956 |
| Springstubb Brendan B | Director |
Mar 04 '25 |
Buy |
8.75 |
5,000 |
43,750 |
11,842 |
8.35%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):